Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice

Neuropharmacology

Volumn 110, Issue , 2016, Pages 143-153

  Wiley, Jenny L ^a   Lefever, Timothy W ^a   Marusich, Julie A ^a   Grabenauer, Megan ^a   Moore, Katherine N ^a   Huffman, John W ^b   Thomas, Brian F ^a  

^a RTI INTERNATIONAL   (United States)

^b CLEMSON UNIVERSITY   (United States)

Author keywords

Alkylindoles; Functional observation battery; JWH 018; Receptor binding; Synthetic cannabinoids

Indexed keywords

1 BUTYL 3 (1 NAPHTHOYL)INDOLE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; DRONABINOL; MIANSERIN; POTASSIUM CHANNEL HERG; SEROTONIN 2B RECEPTOR; 1-PENTYL-3-(1-NAPHTHOYL)INDOLE; INDOLE DERIVATIVE; JWH-073; NAPHTHALENE DERIVATIVE; PROTEIN BINDING; STREET DRUG;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DISCRIMINATION TEST; EXPERIMENTAL BEHAVIORAL TEST; FUNCTIONAL OBSERVATIONAL BATTERY; MALE; MOUSE; MUSCLE TONE; NERVE EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SENSORIMOTOR FUNCTION; URINALYSIS; ANIMAL; C57BL MOUSE; CHEMISTRY; DOSE RESPONSE; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PHYSIOLOGY;

ANIMALS; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRONABINOL; INDOLES; MALE; MIANSERIN; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; NAPHTHALENES; PROTEIN BINDING; RECEPTOR, CANNABINOID, CB1; RECEPTOR, SEROTONIN, 5-HT2B; STREET DRUGS;

EID: 84979653175     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2016.07.016     Document Type: Article

References (59)

1. Aung, M.M., Griffin, G., Huffman, J.W., Wu, M., Keel, C., Yang, B., Showalter, V.M., Abood, M.E., Martin, B.R., Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend. 60 (2000), 133–140.
2. Auwarter, V., Dresen, S., Weinmann, W., Muller, M., Putz, M., Ferreiros, N., 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?. J. Mass Spectrom. 44 (2009), 832–837.
3. 9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci. Biobehav Rev. 16 (1992), 55–62.
4. Barrett, R.L., Wiley, J.L., Balster, R.L., Martin, B.R., Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats. Psychopharmacol. Berl. 118 (1995), 419–424.
5. Bateman, R.H., Carruthers, R., Hoyes, J.B., Jones, C., Langridge, J.I., Millar, A., Vissers, J.P.C., A novel precursor ion discovery method on a hybrid quadrupole orthogonal acceleration time-of-flight (Q-TOF) mass spectrometer for studying protein phosphorylation. J. Amer Soc. Mass Spectrom. 13 (2002), 792–803.
6. Beardsley, P.M., Scimeca, J.A., Martin, B.R., Studies on the agonistic activity of delta 9-11-tetrahydrocannabinol in mice, dogs and rhesus monkeys and its interactions with delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 241 (1987), 521–526.
7. Bowen, S.E., Wiley, J.L., Evans, E.B., Tokarz, M.E., Balster, R.L., Functional observational battery comparing effects of ethanol, 1,1,1-trichloroethane, ether, and flurothyl. Neurotoxicol Teratol. 18 (1996), 577–585.
8. Breivogel, C.S., Childers, S.R., Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J. Pharmacol. Exp. Ther. 295 (2000), 328–336.
9. Brents, L.K., Gallus-Zawada, A., Radominska-Pandya, A., Vasiljevik, T., Prisinzano, T.E., Fantegrossi, W.E., Moran, J.H., Prather, P.L., Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem. Pharmacol. 83 (2012), 952–961.
10. Brents, L.K., Reichard, E.E., Zimmerman, S.M., Moran, J.H., Fantegrossi, W.E., Prather, P.L., Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS ONE, 6, 2011, e21917.
11. Brewer, T.L., Collins, M., A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. J. Spec. Pediatr. Nurs. 19 (2014), 119–126.
12. Center for Disease Control and Prevention, Acute Kidney Injury Associated with Synthetic Cannabinoid Use - Multiple States, 2012. 2013, 93–98 MMWR Morb Mortal Wkly Rep. 62.
13. Chimalakonda, K.C., Seely, K.A., Bratton, S.M., Brents, L.K., Moran, C.L., Endres, G.W., James, L.P., Hollenberg, P.F., Prather, P.L., Radominska-Pandya, A., Moran, J.H., Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab. Dispos. 40 (2012), 2174–2184.
14. Craske, M.G., Rauch, S.L., Ursano, R., Prenoveau, J., Pine, D.S., Zinbarg, R.E., What is an anxiety disorder?. Depress Anxiety 26 (2009), 1066–1085.
15. D'Ambra, T.E., Estep, K.G., Bell, M.R., Eissenstat, M.A., Josef, K.A., Ward, S.J., Haycock, D.A., Baizman, E.R., Casiano, F.M., Beglin, N.C., Chippari, S.M., Grego, J.D., Kullnig, R.K., Daley, G.T., Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J. Med. Chem. 35 (1992), 124–135.
16. Everett, R.M., Descotes, G., Rollin, M., Greener, Y., Bradford, J.C., Benziger, D.P., Ward, S.J., Nephrotoxicity of pravadoline maleate (WIN 48098-6) in dogs: evidence of maleic acid-induced acute tubular necrosis. Fundam. Appl. Toxicol. 21 (1993), 59–65.
17. Every-Palmer, S., Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend. 117 (2011), 152–157.
18. Fantegrossi, W.E., Moran, J.H., Radominska-Pandya, A., Prather, P.L., Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?. Life Sci. 97 (2014), 45–54.
19. Gatch, M.B., Forster, M.J., Delta9-Tetrahydrocannabinol-like discriminative stimulus effects of compounds commonly found in K2/Spice. Behav. Pharmacol. 25 (2014), 750–757.
20. Green, B., Kavanagh, D., Young, R., Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev. 22 (2003), 453–460.
21. Gunderson, E.W., Haughey, H.M., Ait-Daoud, N., Joshi, A.S., Hart, C.L., “Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am. J. Addict. 21 (2012), 320–326.
22. Hancox, J.C., McPate, M.J., El Harchi, A., Zhang, Y.H., The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol. Ther. 119 (2008), 118–132.
23. Haubrich, D.R., Ward, S.J., Baizman, E., Bell, M.R., Bradford, J., Ferrari, R., Miller, M., Perrone, M., Pierson, A.K., Saelens, J.K., et al. Pharmacology of pravadoline: a new analgesic agent. J. Pharmacol. Exp. Ther. 255 (1990), 511–522.
24. Hermanns-Clausen, M., Kneisel, S., Szabo, B., Auwarter, V., Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108 (2013), 534–544.
25. Huffman, J.W., Dai, D., Martin, B.R., Compton, D.R., Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg Med. Chem. Lett. 4 (1994), 563–566.
26. Huffman, J.W., Padgett, L.W., Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr. Med. Chem. 12 (2005), 1395–1411.
27. Huffman, J.W., Szklennik, P.V., Almond, A., Bushell, K., Selley, D.E., He, H., Cassidy, M.P., Wiley, J.L., Martin, B.R., 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med. Chem. Lett. 15 (2005), 4110–4113.
28. Hunault, C.C., Bocker, K.B., Stellato, R.K., Kenemans, J.L., de Vries, I., Meulenbelt, J., Acute subjective effects after smoking joints containing up to 69 mg Delta9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial. Psychopharmacol. Berl. 231 (2014), 4723–4733.
29. Järbe, T.U., Liu, Q., Makriyannis, A., Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats. Psychopharmacol. Berl. 184 (2006), 36–45.
30. Laaris, N., Good, C.H., Lupica, C.R., Delta9-tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus. Neuropharmacology 59 (2010), 121–127.
31. Makriyannis, A., Deng, H., 2005. Cannabimimetic indole derivatives. Patent US6900236, University of Connecticut, Farmington, CT, United States.
32. Manera, C., Tuccinardi, T., Martinelli, A., Indoles and related compounds as cannabinoid ligands. Mini Rev. Med. Chem. 8 (2008), 370–387.
33. Martin, B.R., Compton, D.R., Thomas, B.F., Prescott, W.R., Little, P.J., Razdan, R.K., Johnson, M.R., Melvin, L.S., Mechoulam, R., Ward, S.J., Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40 (1991), 471–478.
34. Marusich, J.A., Antonazzo, K.R., Wiley, J.L., Blough, B.E., Partilla, J.S., Baumann, M.H., Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87 (2014), 206–213.
35. Marusich, J.A., Grant, K.R., Blough, B.E., Wiley, J.L., Effects of synthetic cathinones contained in “bath salts” on motor behavior and a functional observational battery in mice. Neurotoxicology 33 (2012), 1305–1313.
36. Moller, I., Wintermeyer, A., Bender, K., Jubner, M., Thomas, A., Krug, O., Schanzer, W., Thevis, M., Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test. Anal. 3 (2011), 609–620.
37. Moser, V.C., The functional observational battery in adult and developing rats. Neurotoxicology 21 (2000), 989–996.
38. Moser, V.C., Functional assays for neurotoxicity testing. Toxicol. Pathol. 39 (2011), 36–45.
39. Moser, V.C., Boyes, W.K., Prolonged neurobehavioral and visual effects of short-term exposure to 3,3'-iminodipropionitrile (IDPN) in rats. Fundam. Appl. Toxicol. 21 (1993), 277–290.
40. National Research Council, Guide for the Care and Use of Laboratory Animals. 2011, National Academies Press, Washington, D.C.
41. Parker, L.A., Limebeer, C.L., Conditioned gaping in rats: a selective measure of nausea. Auton. Neurosci. 129 (2006), 36–41.
42. Peroutka, S.J., Snyder, S.H., [3H]Mianserin: differential labeling of serotonin and histamine receptors in rat brain. J. Pharmacol. Exp. Ther. 216 (1981), 142–148.
43. Schifano, F., Corazza, O., Deluca, P., Davey, Z., Di Furia, L., Farre, M., Flesland, L., Mannonen, M., Pagani, S., Peltoniemi, T., Pezzolesi, C., Scherbaum, N., Siemann, H., Skutle, A., Torrens, M., Van Der Kreeft, P., Psychoactive drug or mystical incense? Overview of the online available information on Spice products. Int. J. Cult. Ment. Health 2 (2009), 137–144.
44. Selden, B.S., Clark, R.F., Curry, S.C., Marijuana. Emerg. Med. Clin. North Am. 8 (1990), 527–539.
45. Sobolevsky, T., Prasolov, I., Rodchenkov, G., Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci. Int. 200 (2010), 141–147.
46. Tegeris, J.S., Balster, R.L., A comparison of the acute behavioral effects of alkylbenzenes using a functional observational battery in mice. Fundam. Appl. Toxicol. 22 (1994), 240–250.
47. Tseng, A.H., Craft, R.M., CB(1) receptor mediation of cannabinoid behavioral effects in male and female rats. Psychopharmacol. Berl. 172 (2004), 25–30.
48. Vann, R.E., Warner, J.A., Bushell, K., Huffman, J.W., Martin, B.R., Wiley, J.L., Discriminative stimulus properties of Delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice. Eur. J. Pharmacol. 615 (2009), 102–107.
49. Vardakou, I., Pistos, C., Spiliopoulou, C., Spice drugs as a new trend: mode of action, identification and legislation. Toxicol. Lett. 197 (2010), 157–162.
50. Varvel, S.A., Bridgen, D.T., Tao, Q., Thomas, B.F., Martin, B.R., Lichtman, A.H., Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J. Pharmacol. Exp. Ther. 314 (2005), 329–337.
51. Wiebelhaus, J.M., Poklis, J.L., Poklis, A., Vann, R.E., Lichtman, A.H., Wise, L.E., Inhalation exposure to smoke from synthetic “marijuana” produces potent cannabimimetic effects in mice. Drug Alcohol Depend. 126 (2012), 316–323.
52. Wiley, J.L., Compton, D.R., Dai, D., Lainton, J.A., Phillips, M., Huffman, J.W., Martin, B.R., Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J. Pharmacol. Exp. Ther. 285 (1998), 995–1004.
53. Wiley, J.L., Marusich, J.A., Huffman, J.W., Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci. 97 (2014), 55–63.
54. Wiley, J.L., Marusich, J.A., Lefever, T.W., Antonazzo, K.R., Wallgren, M.T., Cortes, R.A., Patel, P.R., Grabenauer, M., Moore, K.N., Thomas, B.F., AB-CHMINACA, AB-PINACA, and FUBIMINA: affinity and potency of novel synthetic cannabinoids in producing delta-9-tetrahydrocannabinol-like effects in mice. J. Pharmacol. Exp. Ther. 354 (2015), 328–339.
55. Wiley, J.L., Marusich, J.A., Lefever, T.W., Cortes, R.A., Cross-substitution of delta-9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats. Pharmacol. Biochem. Behav. 124 (2014), 123–128.
56. Wiley, J.L., Marusich, J.A., Lefever, T.W., Grabenauer, M., Moore, K.N., Thomas, B.F., Cannabinoids in disguise: delta-9-Tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology 75 (2013), 145–154.
57. Williamson, E.M., Evans, F.J., Cannabinoids in clinical practice. Drugs 60 (2000), 1303–1314.
58. Wintermeyer, A., Moller, I., Thevis, M., Jubner, M., Beike, J., Rothschild, M.A., Bender, K., In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal. Bioanal. Chem. 398 (2010), 2141–2153.
59. Yao, B.B., Hsieh, G., Daza, A.V., Fan, Y., Grayson, G.K., Garrison, T.R., El Kouhen, O., Hooker, B.A., Pai, M., Wensink, E.J., Salyers, A.K., Chandran, P., Zhu, C.Z., Zhong, C., Ryther, K., Gallagher, M.E., Chin, C.L., Tovcimak, A.E., Hradil, V.P., Fox, G.B., Dart, M.J., Honore, P., Meyer, M.D., Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J. Pharmacol. Exp. Ther. 328 (2009), 141–151.